|
Workshop
Antibody Drug Conjugates: Chemistry, Biology, Pharmacokinetics and Toxicology
Speakers:
Jagath Junutula (Cellerant), Andy Polson (Genentech) , Toni Kline (Sutro), Chetana Rao (BMS), Donglu Zhang (Genentech), Keyang Xu, PhD (Genentech), Melissa Schutten (Genentech)
Organizers:
Thomas Pillow (Genentech)
Date:
2018-09-12
Time:
8:45-16:00 Pacific Time
Registration fee
(USD): Regular: $195; For unemployed or students: $30; Academic: $125; For major-sponsor rep (incl lunch): $0; For vendor-show rep: $35
Location:
SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date:
(24)AIT Bioscience; Alturas Analytics; Applied StemCell, Inc.; Averica Discovery Services; BioPharmEquip; Bruker; JOINN Labs; KCAS Bioanalytical & Biomarker Services; MabPlex; Medpace; MicroConstants; Pacific BioLabs; PHARMout Laboratories; Promega; Q2 Solutions; QPS; SCIEX; Sekisui XenoTech, LLC; Selvita Inc.; Sepax Technologies; Shimadzu Scientific Instruments, Inc; Sigma Aldrich; SRI International; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2018-09-11
(it will close sooner if the seating cap is reached)
About the Topic
Linking a small-molecule cytotoxic drug to a monoclonal antibody takes the strengths of both while potentially mitigating the liabilities. The resulting bioconjugates, known as antibody−drug conjugates or ADCs, have been validated clinically, with four approved anti-cancer agents for solid and hematological cancers. This workshop will broadly discuss the strategies for designing, constructing and analyzing ADCs utilizing the latest advances in the field.
This workshop will cover the following specific topics:
- Overview of antibody-drug conjugates (ADCs) and clinical progress
- Selecting a target for ADCs
- The chemistry of linkers and drugs
- Site-specific conjugation
- Analytical characterization of ADCs
- ADC bioanalysis & pharmacokinetics
- Preclinical safety/toxicology
Workshop Agenda:
| Time |
Topic |
Presenter |
| 8:45-9:00 |
Welcome and Introduction |
Thomas Pillow |
| 9:00-9:45 |
1. ADC Discovery & Development |
Jagath Junutula |
| 9:45-10:30 |
2. ADCs for Hematological Malignancies |
Andy Polson |
| 10:30-10:45 |
Break |
|
| 10:45-11:30 |
3. Conjugation Modalities for ADC Generation |
Chetana Rao |
| 11:30-12:30 |
Lunch |
|
| 12:30-1:15 |
4. ADC Chemistry |
Toni Kline |
| 1:15-2:00 |
5. Small Molecule DMPK for ADCs |
Donglu Zhang |
| 2:00-2:15 |
Break |
|
| 2:15-3:00 |
6. Bioanalysis of ADCs |
Keyang Xu |
| 3:00-3:45 |
7. ADC Safety/Toxicity |
Melissa Schutten |
| 3:45-4:15 |
Panel Discussion |
All |
| 4:15-4:30 |
Final Remarks |
Thomas Pillow |
2019-12-10, In Vitro Diagnostics (IVD) & Companion Diagnostics (CDx): Guiding Clinical Trials and Patient Treatment through Precision Medicine
|
2020-01-10, All about half-life: which one should I use? (tentative title)
|
2020-01-21, Considerations for Successful Clinical Development: Fundamentals and Best Practices for Clinical Trial Design, Biostatistics, and Data Management
|
2020-02-11, Development of Drug/Device Combinations
|
2020-02-24, MS Courses by Dr. Jack Henion: Advanced LC-MS/MS (Day1) & Interpretation of MS/MS CID Spectra (Day2)
|
2020-03-09, Animal Pharmacology Models for Oncology Drug Development
|
2020-03-16, Clinical Trials Essentials: An Intensive One-Week Course (register for the full week or half day sessions)
|
2020-04-10, Development of Multivalent Protein Conjugates as a Strategy to Engineer Drug Pharmacology
|
2020-05-12, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
|
2020-05-22, No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond
|
2020-06-23, Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Origin Bioanalytical Laboratory
Sacramento-based CRO for bioanalytical method development, validation, and consulting of LC-MS/MS analysis, specializing in ocular matrices
|
Adesis Inc.
Adesis provides expertise in custom synthesis, process dev, R&D, and specialty mfg. to pharma, chemical, biomaterials, and catalysts companies
|
Pacific BioLabs
Bay Area CRO with 37 years experience in Methods Development & Validation, Bioanalysis, Toxicology, Immunogenicity, Stability Studies & Microbiology
|
Alturas Analytics, Inc.
Expert GLP & non-GLP LC-MS/MS & GC-MS/MS bioanalytical quantitation services of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|